Table V.

Enhancement ratios^a due to combined treatment with nicotinamide or mild temperature hyperthermia.

Variable	Nicotinamide	MTH
Surviving fraction = 0.3
Total cell population
Without bevacizumab
Without 10B-carrier	1.3±0.15	1.2±0.1
With BPAc	1.25±0.1	1.4±0.15
With BSHd	1.5±0.15	1.2±0.1
With bevacizumab
Without 10B-carrier	1.2±0.1	1.1±0.1
With BPA	1.15±0.1	1.35±0.15
With BSH	1.3±0.15	1.15±0.1
Net micronucleus frequency = 0.3
Total cell population
Without bevacizumab
Without 10B-carrier	1.25±0.1	1.15±0.1
With BPA	1.15±0.1	1.3±0.1
With BSH	1.4±0.1	1.2±0.1b
With bevacizumab
Without 10B-carrier	1.1±0.1	1.15±0.1
With BPA	1.1±0.1	1.2±0.1
With BSH	1.2±0.1	1.15±0.1c
Quiescent cell population
Without bevacizumab
Without 10B-carrier	1.1±0.1	1.2±0.1
With BPA	1.15±0.1d	1.4±0.1d
With BSH	1.2±0.1e	1.45±0.15b,e
With bevacizumab
Without 10B-carrier	1.05±0.1	1.15±0.1
With BPA	1.1±0.1f	1.35±0.15f
With BSH	1.15±0.1g	1.4±0.15c,g

Data are presented as mean ± standard error (n=9).

^aRatio of the dose of radiation necessary to obtain each end-point without combined treatment to that needed to obtain each end-point with the combined treatment; MTH, mild temperature hyperthermia; BPA, L-para-boronophenylalanine-¹⁰B; BSH, sodium mercaptoundecahydrododecaborate-¹⁰B;

^b–gDifferences between two values labeled with the same letter are significant (P<0.05).